Skip to content

Anti-oxidative function and composition of high-density-lipoprotein (HDL) in the polycystic ovary syndrome

Anti-oxidative function and composition of high-density-lipoprotein (HDL) in the polycystic ovary syndrome - HDL function in PCOS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON30680
Enrollment
44
Registered
2007-01-23
Start date
2007-02-14
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-oxidative HDL function

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cases: PCOS+, BMI >=27, HOMA >=1.5, 25-40 years of age Controls: PCOS-, BMI

Exclusion criteria

Exclusion criteria: Diabetes mellitus Oral contraceptives Lipid lowering medication Pregnancy Familial hypercholesterolemia Hypertriglyceridemia Clinically manifest cardiovascular disease

Design outcomes

Primary

MeasureTime frame
Difference in anti-oxidative capacity of HDL between obese PCOS women with reduced insulin sensitivity and lean controls with normal insulin sensitivity. During oxidation of LDL conjugated dienes are released. Addition of HDL can inhibit the rate of oxidation of LDL; as a consequence less conjugated diens are being released. In the current study, the difference in conjugated dienes between PCOS and controls will be compared. NB the anti-oxidative capacity of HDL is measured and expressed independently of the total amount of HDL

Secondary

MeasureTime frame
Difference in composition of HDL between obese PCOS women with reduced insulin sensitivity and lean controls with normal insulin sensitivity. The composition of HDL particles. Using ultracentrifugation subfractions of HDL will be isolated: HDL2a,2b,3a,3b,3c. In these fractions cholesterol, triglycerides, phospholipids and apolipoproteins will be determined. The composition of these subfractions will be compared between PCOS and controls. As an exploratory parameter the number of endothelial progenitor cells will be determined in PCOS and in controls.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)